Will Abbott Laboratories (NYSE: ABT) Remain a Global Leader in Healthcare?

January 24, 2018, 14:51 pm ET, BY Simon M.- Contributor| Editor: Thomas H. Kee Jr. (Follow on LinkedIn)

Abbott Laboratories (NYSE: ABT) has established itself as a global leader in the healthcare industry with over 90,000 employees in 150 countries worldwide. The company has continuously reinvented itself under the astute leadership of its current CEO Miles White since he assumed the company’s top position in 1998.

Article Summary

Abbott Laboratories is a global leader in the healthcare industry.

The company’s CEO is largely responsible for the company’s success.

The company is a leader in medical devices, generic drugs and nutritional products.

Here’s the trading report on ABT.

The company’s main focus is on medical devices, branded generic medicines, diagnostic products and services as well as nutritional products. The company spun off half of its operations, which were focused on the research and development of pharmaceutical drugs, in January 2013 to form AbbVie Inc (NYSE: ABBV).  

The healthcare company is a good example of the impact a good leader can have on the success of an organization by boldly steering it in new directions while anticipating future consumer trends. Miles White transformed the company from a traditional company that had maintained the same focus since its founding in 1888 into a company that was focused on innovation, acquisitions and divestitures.

The company currently competes on an equal footing with other industry leaders such as Merck & Co., Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) and boasts of world leading drugs such as Humira, which is marketed by AbbVie, but was developed by Abbott. Mr. White identified the huge demand for generic drugs in emerging markets by acquiring companies such as CFR Pharmaceuticals, which doubled its Latin America market.

The company has made many acquisitions and divestitures ever since Miles White assumed the CEO position, which is a crucial growth strategy that has allowed the company to stay ahead of its competitors. The company is currently a global leader in the development of generic drugs and adult nutritional products as well as a leader in the US baby nutrition industry.

Abbott’s current growth trajectory indicates that 2018 might be a stellar year for the company under the innovative leadership of Miles White.

However, it is not enough to know that a stock is likely to head higher, or lower this year. As an investor or trader, it is important to time your entry and exit points accurately in order to minimize risk and maximize your profit potential.

Stock Traders Daily provides risk-controlled strategies that are tailored to different trading and investment styles in order to protect your investment capital and to generate substantial returns for all our subscribers.

Review Our Trading Strategies Here.

Support and Resistance Plot Chart for

Real Time Updates for Repeat Institutional Readers:

Factset: Request User/Pass

Bloomberg, Reuters, Refinitiv, Zacks, or IB users: Access Here.